Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Top Cited Papers
- 9 March 2007
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 101 (7) , 1483-1492
- https://doi.org/10.1016/j.rmed.2007.01.011
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Basophil allergen threshold sensitivity: a useful approach to anti‐IgE treatment efficacy evaluationAllergy, 2006
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Assessment of asthma control and severityAnnals of Allergy, Asthma & Immunology, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical and Experimental Allergy, 2004
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992